All News

Found 123 articles

• Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

  8/1/2022

  Gracell Biotechnologies Inc. today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO).

• Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference

  7/26/2022

  Gracell Biotechnologies Inc. today announced that the management team will participate in BTIG 2022 Hybrid Biotechnology Conference in August 2022.

• Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

  7/19/2022

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the appointment of Samuel Zhang, Ph.D., as its Chief Business Officer.

• Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences - June 14, 2022

  6/14/2022

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows.

• Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients

  6/12/2022

  Gracell Biotechnologies Inc. announced the updated clinical data from a multicenter study evaluating GC012F, the Company's autologous CAR-T therapeutic candidate dual-targeting B-cell maturation antigen and CD19, for the treatment of relapsed/refractory multiple myeloma.

• Emerging Era Of CAR T Cell Therapies Market

  6/9/2022

  Kuick Research Report Gives Insight On 600 CAR T Cell Therapies In Clinical Trials.

• Gracell Biotechnologies Schedules Clinical Update Call After EHA2022

  6/3/2022

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), today announced that the Company plans to hold a clinical update call on June 13 after the European Hematology Association 2022 Hybrid Congress (EHA 2022) as the data is subject to meeting's embargo policy until June 12.

• 

  Market Reacts to New Data from Mirati's Lumakras Competitor and More Trial News

  5/27/2022

  Mirati Therapeutics' adagrasib is going up against Amgen’s Lumakras in the KRAS race, and according to Friday pre-market trading, the results shared Thursday don't seem to be enough for investors. 

• Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting

  5/26/2022

  Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), today announced that it will present updated clinical data from a multicenter investigator-initiated trial (IIT) evaluating GC012F, the company's B-cell maturation antigen (BCMA) and CD19 dual-targeting CAR-T candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM) in an oral abstract presentation at the 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting.

• Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

  5/19/2022

  Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows:

• Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update

  5/16/2022

  Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update.

• Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

  5/12/2022

  Gracell Biotechnologies Inc. announced the details of three abstracts that it will present at the European Hematology Association 2022 Hybrid Congress, being held from June 9 – June 12 in Vienna, Austria.

• Gracell Biotechnologies to Participate in Three Investor Conferences in May 2022

  5/4/2022

  Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in May 2022 as follows.

• Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

  5/2/2022

  Gracell Biotechnologies Inc. today announced that it plans to release unaudited financial results for the first quarter ended March 31, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, May 16, 2022.

• Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

  4/28/2022

  Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of its oral abstract presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021

  4/22/2022

  Gracell Biotechnologies Inc. announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2021 with the U.S. Securities and Exchange Commission on April 22, 2022.

• Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting

  4/14/2022

  Gracell Biotechnologies Inc. today announced that its abstract providing the follow-up clinical data of GC012F in the treatment of relapsed/refractory multiple myeloma (RRMM) has been selected for oral presentation as part of an Oral Abstract Session at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL

  4/8/2022

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

• Gracell Biotechnologies to Participate in Three Investor Conferences in April 2022

  3/29/2022

  Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in April 2022 as follows:

• Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update

  3/14/2022

  Gracell Biotechnologies Inc. today reported fourth quarter and full year unaudited financial results for the period ended December 31, 2021, and provided corporate updates.